1-9 of 9
Anders Själander
Close
Sort by
Journal Articles

No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries

Niklas Gunnarsson, MD, Martin Höglund, MD PhD, Leif Stenke, MD PhD, Fredrik Sandin, MSc, Magnus Bjorkholm, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevärn, MD, Ulla Olsson-Strömberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD, Anders Själander, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1896.
https://doi.org/10.1182/blood.V128.22.1896.1896
Published: 2016
Journal Articles

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Mette Ilander, Heinrich Schlums, Ulla Olsson-Strömberg, Hanna Lähteenmäki, Tiina Kasanen, Perttu Koskenvesa, MD, Stina Söderlund, Martin Höglund, Ass Prof, Berit Markevärn, Anders Själander, Kourosh Lotfi, Claes Malm, Anna Lubking, MD, Marja Ekblom, Elena Holm, Mats Björeman, Sören Lehmann, Leif Stenke, MD PhD, Lotta Ohm, Waleed Majeed, MD, Martin C. Muller, Hans Ehrencrona, Henrik Hjorth-Hansen, MD PhD, Susanne Saussele, Francois-Xavier Mahon, MD PhD Professor, Kimmo Porkka, MD PhD, Joelle Guilhot, PhD, Yenan Bryceson, Johan Richter, MD PhD, Satu Mustjoki, MD PhD
Journal: Blood
Blood (2015) 126 (23): 343.
https://doi.org/10.1182/blood.V126.23.343.343
Published: 2015
Journal Articles

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Niklas Gunnarsson, MD, Martin Hoglund, MD PhD, Leif Stenke, MD PhD, Solveig Wallberg Jonsson, MD PhD, Fredrik Sandin, PhD, Magnus Bjorkholm, MD PhD, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevarn, MD, Ulla Olsson-Stromberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD PhD, Anders Sjalander, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1586.
https://doi.org/10.1182/blood.V126.23.1586.1586
Published: 2015
Journal Articles

Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries

Torsten Dahlén, MD, Gustaf Edgren, MD PhD, Martin Höglund, MD PhD, Mats Lambe, MD PhD, Magnus Björkholm, MD PhD, Fredrik Sandin, PhD, Anders Själander, MD PhD, Johan Richter, MD PhD, Lotta Ohm, MD PhD, Magnus Bäck, MD PhD, Leif Stenke, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3134.
https://doi.org/10.1182/blood.V124.21.3134.3134
Published: 2014
Journal Articles

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Mette Matilda Ilander, MSc, Ulla Olsson-Strömberg, MD PhD, Hanna Lähteenmäki, MSc, Kasanen Tiina, Perttu Koskenvesa, MD, Stina Söderlund, MD, Martin Höglund, MDPhD, Berit Markevärn, MD, Anders Själander, MD PhD, Kourosh Lotfi, MDPhD, Claes Malm, MD, Anna Lubking, MD, Marja Ekblom, MD PhD, Elena Holm, MD, Mats Björeman, MD, Sören Lehmann, MD PhD, Leif Stenke, MD PhD, Lotta Ohm, MD PhD, Waleed Majeed, MD, Markus Pfirrmann, PhD, Martin C Muller, MD, Joelle Guilhot, PhD, Hans Ehrencrona, MD PhD, Henrik Hjorth-Hansen, MD PhD, Susanne Saussele, Francois-Xavier Mahon, MD PhD, Kimmo Porkka, MD PhD, Johan Richter, MD PhD, Satu Mustjoki, MDPhD
Journal: Blood
Blood (2014) 124 (21): 812.
https://doi.org/10.1182/blood.V124.21.812.812
Published: 2014
Journal Articles

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Niklas Gunnarsson, MD, Stenke Leif, MD PhD, Martin Höglund, MD PhD, Fredrik Sandin, PhD, Magnus Björkholm, MD PhD, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevärn, MD, Ulla Olsson-Strömberg, MD PhD, Johan Richter, MD PhD, Hans Wadenvik, MD PhD, Jonas Wallvik, MD PhD, Anders Själander, MD PhD
Journal: Blood
Blood (2014) 124 (21): 154.
https://doi.org/10.1182/blood.V124.21.154.154
Published: 2014
Journal Articles

Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI

Mette Matilda Ilander, MSc, Ulla Olsson-Strömberg, MD, PhD, Hanna Lähteenmäki, MSc, Tiina Kasanen, Perttu Koskenvesa, MD, Stina Söderlund, MD, Martin Hoglund, MD, PhD, Berit Markevärn, MD, Anders Själander, MD, PhD, Kourosh Lofti, MD, PhD, Claes Malm, MD, Anna Lubking, MD, Marja Ekblom, MD, PhD, Elena Holm, MD, Mats Björeman, MD, Sören Lehmann, MD, PhD, Leif Stenke, MD, PhD, Lotta Ohm, MD, Henrik Hjorth-Hansen, MD, PhD, Susanne Saussele, MD, Francois-Xavier Mahon, MD, PhD, Kimmo Porkka, MD, PhD, Johan Richter, MD, PhD, Satu Mustjoki, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 379.
https://doi.org/10.1182/blood.V122.21.379.379
Published: 2013
Journal Articles

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström, Mats Björeman, Magnus Björkholm, Mats Brune, Arta Dreimane, Marja Ekblom, Sören Lehmann, Per Ljungman, Claes Malm, Berit Markevärn, Kristina Myhr-Eriksson, Lotta Ohm, Ulla Olsson-Strömberg, Anders Själander, Hans Wadenvik, Bengt Simonsson, Leif Stenke, Johan Richter
Journal: Blood
Blood (2013) 122 (7): 1284–1292.
https://doi.org/10.1182/blood-2013-04-495598
Published: 2013
Journal Articles

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Clinical Trials & Observations
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, Anders Almqvist, Mats Björeman, Max Flogegård, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr-Eriksson, Lotta Ohm, Anu Räsänen, Marjatta Sinisalo, Anders Själander, Ulla Strömberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Fredrik Sandin, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Kimmo Porkka, for the Nordic CML Study Group
Journal: Blood
Blood (2011) 118 (12): 3228–3235.
https://doi.org/10.1182/blood-2011-02-336685
Published: 2011